STARNSEStrides Pharma Science Limited· PharmaceuticalsMinimalNeutral
Announced Mon, 18 May · 16:54 IST

Strides Pharma Science Limited has informed the Exchange about change in Management

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.6%1-day move
₹1105.00
prior close
₹1124.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.7-6.8-7.1-3.7+3.6+5.3+3.5+7.2+5.4+2.3-11.6+1.2-4.5
Up moveDown movePending
AI summary

Strides Pharma Science announced several management changes approved by its Board on May 18, 2026. Ram (Venkata Seetharama Raju Pakalapati), currently Chief Operating Officer, has been elevated to Executive Director and KMP effective June 1, 2026, having served the company for over 18 years. Aditya Arun Kumar, son of Founder and Chairperson Arun Kumar, has stepped down from his Executive Director role and been redesignated as Non-Executive Director, ceasing to be KMP from May 31, 2026. This move aligns with the promoters' intention to further professionalize management. Additionally, Nandini Matiyani (Executive VP-HR) and Ariff Khan (Executive VP-Manufacturing Operations) have been nominated as SMPs, effective June 1, 2026. The filing also corrected a typographical error in an earlier disclosure.

Likely market impact

The elevation of internal talent like Ram to the Board and Aditya's transition to a non-executive role signals ongoing professionalization of Strides' management structure. This may be viewed positively by investors as it demonstrates structured succession planning.